drug_type
RELEVANT_DRUG
intervention_type
Biological (adoptive cellular therapy)
drug_description
Donor-derived, partially HLA-matched virus-specific T lymphocytes enriched for IFN-γ–secreting CD8+/CD4+ T cells reactive to adenovirus, CMV, and EBV antigens; manufactured using CliniMACS cytokine capture and infused to restore antiviral immunity by HLA-restricted recognition and cytotoxic killing of infected cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
T-Lymphocytes, Cytotoxic
drug_category
TCR SELECTED T CELLS
drug_class
Unedited cells
drug_delivery_route
Intravenous
drug_mechanism_of_action
Adoptive transfer of donor-derived, partially HLA-matched virus-specific CD8+/CD4+ T cells selected for IFN-γ secretion. These unengineered T cells use native TCRs to recognize HLA-presented adenovirus/CMV/EBV peptides on infected cells, secrete Th1 cytokines, and kill targets via perforin/granzyme, restoring antiviral immunity.
drug_name
Specific T-Lymphocytes (donor-derived virus-specific T cells, VSTs)
nct_id_drug_ref
NCT06027879